

ACTIVATION OF THE c-K-ras ONCOGENE IN A HUMAN PANCREAS CARCINOMA

Hisamaru Hirai¹, Tetsuro Okabe, Yumi Anraku, Michio Fujisawa,
Akio Urabe and Fumimaro Takaku

The Third Department of Internal Medicine,
Faculty of Medicine, University of Tokyo,
7-3-1 Hongo, Tokyo 113, Japan

Received January 14, 1985

Summary: The human pancreas carcinoma cell line T3M-4 contains activated c-Kirsten(K)-ras oncogene detectable by the DNA-mediated gene transfer technique using NIH/3T3 cells. DNA fragments containing coding lesions have been cloned, and nucleotide sequence analysis suggests that the T3M-4 oncogene has been activated by a single nucleotide transition from A to C in the second exon, which results in the substitution of histidine for glutamine in codon 61 of the predicted amino acid sequence. The quantity analysis of c-K-ras oncogene in the DNA and RNA of T3M-4 cells revealed that the c-K-ras gene was amplified and overexpressed in T3M-4 cells. These findings indicate that the T3M-4 c-K-ras oncogene is activated by different mutational events. © 1985 Academic Press, Inc.

Several oncogenes of human malignant tumors have been detected by their ability to induce morphological transformation of NIH/3T3 cells (for review 1-3). Most oncogenes so far detected belong to the ras gene family (for review 2,3), which consists of three proto-oncogenes, c-Harvey(H)-ras, c-Kirsten(K)-ras, and N-ras. Molecular cloning and nucleotide sequence analysis of the ras genes from human tumors revealed that a single point mutation in codon 12 or 61 of the predicted p21 protein is responsible for the transforming activity. We report here the cloning and identification of the lesion responsible for activation of c-K-ras oncogene from human pancreas carcinoma cell line T3M-4. The c-K-ras gene is amplified and overexpressed in T3M-4 cells. Thus, the T3M-4 c-K-ras gene is activated by different mutational events.

MATERIALS AND METHODS

Cells and transfection assay: The T3M-4 cell line was established from a Japanese male patient with primary pancreatic exocrine adenocarcinoma (4).

¹To whom correspondence should be addressed.

T3M-4 cells produce carcinoembryonic antigen in vitro in culture and in vivo in nude mice (4). DNA transfection assays using NIH/3T3 cells were performed by the calcium phosphate precipitation methods (5), as described previously (6).

Analysis of DNAs from transformed cells: Twenty μg of high molecular weight DNA were digested with appropriate restriction endonucleases, electrophoresed through 0.8% agarose gels and blotted to nitrocellulose filters as described by Southern (7). The resulting blots were hybridized with radioactive probes.

RNA dot blot hybridization: Poly(A)⁺RNA doubling dilutions were prepared and denatured, and 5 μl samples (1 μg poly(A)⁺RNA per original spot) were spotted onto a nitrocellulose filter (8). Hybridization was carried out as described by Thomas (8).

Molecular cloning: DNA from the NIH/3T3 secondary transformant was digested to completion with the restriction endonuclease EcoRI, and fragments of different sizes were fractionated by agarose gel electrophoresis and purified by the electroelution method. DNA of the $\lambda\text{gtWES}\cdot\lambda\text{B}$ phage vector was digested with EcoRI and purified by preparative sucrose gradient centrifugation. Purified phage arms and cellular DNA fragments were ligated at 1:1 molar ratio by T4 DNA ligase and packaged in vitro into phage particles (9). Positive plaques were identified by in situ hybridization of phage plaques (10).

Nucleotide sequence analysis: Sequences were determined by the chain terminator method (11) after subcloning suitable restriction enzyme-generated DNA fragments into phage M13 mp10 and mp11 replicative form DNAs.

RESULTS

Identification of the T3M-4 oncogene: When high molecular weight DNA of T3M-4 cells was subjected to transfection analysis using NIH/3T3 cells, a relatively high level of focus formation was observed (efficiency, 0.06 focus per μg DNA). The transforming activity was increased 1.5 fold by a second cycle of transfection using high molecular weight DNA of primary NIH/3T3 transformants. All the transformants obtained were transplantable to nude mice. To confirm that the foci observed were induced by human DNA, the DNAs of transformants were subjected to Southern blotting analysis using a probe specific for human Alu-family repetitive sequences (12). Primary transformants demonstrated numerous bands containing human repetitive sequences (Fig. 1A), and secondary transformants retained a relatively few Alu-related fragments (Fig. 1B). In view of evidence relating transforming genes of a number of human tumors to ras genes (2,3), we analyzed T3M-4 transformant DNAs for sequences homologous to these onc genes. Neither N-ras (13) nor H-ras probes (14) detected any fragments other than their endogenous mouse related fragments (data not shown). The K-ras probe (14) specifically




Figure 1. Identification of the T3M-4 oncogene by Southern blot analysis. Twenty μ g of high molecular weight DNA was digested with *Eco*RI, electrophoresed, blotted, and hybridized to 32 P-labeled human repetitive sequence DNA fragment purified from Blur-8 (12) (A and B) or to 32 P-labeled v-K-ras-specific DNA fragment purified from pHHi-3 (14) (C and D). Lane a, NIH/3T3 primary transformant (29L4-8) DNA; lanes b and f, NIH/3T3 primary transformant (29L4-12) DNA; lane c, NIH/3T3 secondary transformant (32L4-6) DNA; lanes d and i, NIH/3T3 secondary transformant (32L4-2) DNA; lanes e and h, T3M-4 DNA; lanes g and j, NIH/3T3 DNA.

detected the presence of human c-K-ras *Eco*RI-fragments of 6.7, 4.7 and 3.0 kb in DNAs of T3M-4 transformants (Fig. 1C and D).

c-K-ras amplification and overexpression in T3M-4 cells: We analyzed the quantity of c-K-ras in the DNA of T3M-4 cells by digestion with restriction endonucleases. The signals obtained in the experiment illustrated by Fig. 2A indicated that c-K-ras is amplified approximately 4-fold in T3M-4 cells. However, we observed that neither N-ras nor c-H-ras gene is amplified in T3M-4 DNA (data not shown). For the expression of c-K-ras in the T3M-4 cell line, the analysis by RNA dot blot hybridization was performed. The expression of c-K-ras in T3M-4 cells was enhanced 4- to 8-fold greater than in normal human pancreatic cells or placental cells (Fig. 2B). The comparative RNA dot hybridization did not detect any difference in the expression level of c-H-ras or N-ras gene among those cells (data not shown).

Molecular cloning and nucleotide sequence of the coding exons of the T3M-4 oncogene: The structure of the human c-K-ras gene has been reported (15,16), and the nucleotide sequence of the coding lesions of c-K-ras gene has been determined (15-17). We cloned four *Eco*RI-fragments containing coding exons




Figure 2. c-K-ras amplification and overexpression in T3M-4 cells. (A) Southern blot analysis with K-ras-specific probe (pHiHi-3). EcoRI-digested DNA was electrophoresed, blotted, and hybridized. Lane a, 20 μg of T3M-4 DNA; lane b, 5 μg of T3M-4 DNA; lane c, 20 μg of human placental DNA. (B) Dot blot analysis with K-ras-specific probe (pHiHi-3). Lane d, poly(A)⁺RNA from human placental cells; lane e, poly(A)⁺RNA from normal pancreatic cells; lane f, poly(A)⁺RNA from T3M-4 cells.

(Fig. 3) because human c-K-ras gene spans a lesion of at least 30 kb (15,16). The small fragments of the cloned inserts were subcloned into M13 vectors and were sequenced. Sequence comparisons of the coding exons from the T3M-4 and the normal c-K-ras gene revealed a single nucleotide difference in coden 61. The T3M-4 c-K-ras encodes histidine (CAC) in coden 61 while normal c-K-ras encodes glutamine (CAA) (Fig. 4).




Figure 3. Four DNA fragments cloned from the NIH/3T3 secondary transformant (32L4-2) DNA. The restriction map of c-K-ras gene and the localization of coding exons are based on the data of Shimizu et al. (15). λPK6.7, λPK3.0 and λPK3.1 were cloned by v-K-ras-specific fragment from pHiHi-3, and λPK2.4 was cloned by v-K-ras-specific fragment from pKBE-2 (14). Exons 1-4B are denoted by solid blocks. Arrows indicate lesions sequenced. Restriction endonuclease sites are: E, EcoRI; R, RsaI; S, Sau3A; T, TaqI; A, AluI; X, XbaI; H, HindIII.

Exon 1

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Met	Thr	Glu	Tyr	Lys	Leu	Val	Val	Val	Gly	Ala	Gly	Gly	Val	Gly
ATG	ACT	GAA	TAT	AAA	CTT	GTG	GTA	GTT	GGA	GCT	GGT	GGC	GTA	GGC

16	17	18	19	20	21	22	23	24	25	26	27	28	29	30
Lys	Ser	Ala	Leu	Thr	Ile	Gln	Leu	Ile	Gln	Asn	His	Phe	Val	Asp
AAG	AGT	GCC	TTG	ACG	ATA	CAG	CTA	ATT	CAG	AAT	CAT	TTT	GTG	GAC

31	32	33	34	35	36	37
Glu	Tyr	Asp	Pro	Thr	Ile	Glu
GAA	TAT	GAT	CCA	ACA	ATA	GAG

↑

Exon 2

38	39	40	41	42	43	44	45	46	47	48	49	50	51	52
Asp	Ser	Tyr	Arg	Lys	Gln	Val	Val	Ile	Asp	Gly	Glu	Thr	Cys	Leu
GAT	TCC	TAC	AGG	AAG	CAA	GTA	GTA	ATT	GAT	GGA	GAA	ACC	TGT	CTC

53	54	55	56	57	58	59	60	61	62	63	64	65	66	67
Leu	Asp	Ile	Leu	Asp	Thr	Ala	Gly	His	Glu	Glu	Tyr	Ser	Ala	Met
TTG	GAT	ATT	CTC	GAC	ACA	GCA	GGT	CAC	GAG	GAG	TAC	AGT	GCA	ATG

↑
A
Gln

68	69	70	71	72	73	74	75	76	77	78	79	80	81	82
Arg	Asp	Gln	Tyr	Met	Arg	Thr	Gly	Glu	Gly	Phe	Leu	Cys	Val	Phe
AGG	GAC	CAG	TAC	ATG	AGG	ACT	GGG	GAG	GGC	TTT	CTT	TGT	GTA	TTT

83	84	85	86	87	88	89	90	91	92	93	94	95	96	97
Ala	Ile	Asn	Asn	Thr	Lys	Ser	Phe	Glu	Asp	Ile	His	His	Tyr	
GCC	ATA	AAT	AAT	ACT	AAA	TCA	TTT	GAA	GAT	ATT	CAC	CAT	TAT	AG

↑

Figure 4. The DNA sequence and predicted amino acid sequence of the entire first and second exons of the T3M-4 c-K-ras oncogene. A single base change (A to C) and the consequent amino acid change of glutamine to histidine are boxed. The known RNA splice sites are marked by arrows (15-17).

DISCUSSION

In a number of human tumors, ras genes have undergone point mutations that confer to them oncogenic potential in the NIH/3T3 assay (15,17-24). In each case so far analyzed, the lesion responsible for transforming capability in the NIH/3T3 assay has been localized to a single point mutation in coden 12 or 61 of a member of ras genes (15,17-24). It remains to be determined how point mutations in coden 12 or 61 can so markedly affect normal ras functions as well as whether the mechanism of cell transformation by activation in coden 12 is the same as that by activation in coden 61. However, almost all of the c-K-ras genes activated have been found changed in coden 12 (15, 17,23,24). The T3M-4 c-K-ras oncogene was activated by the single base substitution in coden 61 and by the amplification and overexpression. The am-

plification and overexpression may play an additional role in the transforming activity of the T3M-4 c-K-ras gene.

Another suggestion is that the amplification and enhanced expression of cellular oncogenes may contribute to the maintenance of the neoplastic phenotype (25). The amplification and enhanced expression of cellular oncogenes have been found in several tumor cells (25-28). However, any mutational configuration of these amplified oncogenes, such as a rearrangement or a single point mutation, has not been detected (25). In the present case, it has not been understood whether both alleles suffer the point mutation or whether the mutated allele is amplified. Nonetheless, our observation of the oncogene activation by different mutational events may provide circumstantial evidence for multi-step process of carcinogenesis.

ACKNOWLEDGMENTS

We are grateful to E.M. Scolnick and R.A. Weinberg for providing molecular clones. This research was supported in part by Grants-in-Aid for Cancer Research from the Ministry of Health and Welfare and from the Ministry of Education, Science and Culture of Japan.

REFERENCES

1. Cooper, G.M. (1982) *Science* 218, 801-806.
2. Bishop, J.M. (1983) *Annu. Rev. Biochem.* 52, 301-354.
3. Land, H., Parada, L.F., and Weinberg, R.A. (1983) *Science* 222, 771-778.
4. Okabe, T., Yamaguchi, N., and Ohsawa, N. (1983) *Cancer* 51, 662-668.
5. Graham, F.L., and van der Eb, A.J. (1973) *Virology* 52, 456-467.
6. Copeland, N.G., and Cooper, G.M. (1979) *Cell* 16, 347-356.
7. Southern, E.M. (1975) *J. Mol. Biol.* 98, 503-517.
8. Thomas, P.S. (1980) *Proc. Natl. Acad. Sci. U.S.A.* 77, 5201-5205.
9. Hohn, B. (1979) *Methods Enzymol.* 68, 299-309.
10. Benton, W., and Davis, R. (1977) *Science* 196, 180-182.
11. Sanger, F. (1981) *Science* 214, 1305-1312.
12. Jelinek, W.R., Toomey, T.P., Leinwand, L., Duncan, C.H., Biro, P.A., Choudary, P.V., Weissman, S.M., Rubin, C.M., Houck, C.M., Deininger, P.L., and Schmid, C.W. (1980) *Proc. Natl. Acad. Sci. U.S.A.* 77, 1398-1402.
13. Murray, M.J., Cunningham, J.M., Parada, L.F., Dautry, F., Lebowitz, P., and Weinberg, R.A. (1983) *Cell* 33, 749-757.
14. Ellis, R.W., DeFeo, D., Shih, T.Y., Gonda, M.A., Young, H.A., Tsuchida, N., Lowy, D.R., and Scolnick, E.M. (1981) *Nature* 292, 506-511.
15. Shimizu, K., Birnbaum, D., Ruley, M.A., Fasano, O., Suard, Y., Edlund, L., Taparowsky, E., Goldfarb, M., and Wigler, M. (1983) *Nature* 304, 497-500.
16. McGrath, J.P., Capon, D.J., Smith, D.H., Chen, E.Y., Seeburg, P.H., Goeddel, D.V., and Levinson, A.D. (1983) *Nature* 304, 501-506.
17. Capon, D.J., Seeburg, P.H., McGrath, J.P., Hayflick, J.S., Edman, U., Levinson, A.D., and Goeddel, D.V. (1983) *Nature* 304, 507-513.

18. Taparowsky, E., Shimizu, K., Goldfarb, M., and Wigler, M. (1983) *Cell* 34, 581-586.
19. Tabin, C.J., Bradley, S.M., Bargmann, C.I., Weinberg, R.A., Papageorge, A.G., Scolnick, E.M., Dhar, R., Lowy, D.R., and Chang, E.H. (1982) *Nature* 300, 143-149.
20. Reddy, E.P., Reynolds, R.K., Santos, E., and Barbacid, M. (1982) *Nature* 300, 149-152.
21. Taparowsky, E., Suard, Y., Fasano, O., Shimizu, K., Goldfarb, M., and Wigler, M. (1982) *Nature* 300, 762-765.
22. Yuasa, Y., Srivastava, S.K., Dunn, C.Y., Rhim, J.S., Reddy, E.P., and Aaronson, S.A. (1983) *Nature* 303, 775-779.
23. Nakao, H., Yamamoto, F., Neville, C., Evans, D., Mizuno, T., and Perucho, M. (1984) *Proc. Natl. Acad. Sci. U.S.A.* 81, 71-75.
24. Santos, E., Martin-Zanca, D., Reddy, E.P., Pierotti, M.A., Porta, G.D., and Barbacid, M. (1984) *Science* 223, 661-664.
25. Schwab, M., Alitalo, K., Varmus, H., Bishop, J.M., and George, D. (1983) *Nature* 303, 497-501.
26. Collins, S., and Groudine, M. (1982) *Nature* 298, 679-681.
27. Dalla-Favera, R., Wong-Staal, F., and Gallo, R. (1982) *Nature* 299, 61-63.
28. Collins, S.J., and Groudine, M.T. (1983) *Proc. Natl. Acad. Sci. U.S.A.* 80, 4813-4817.